{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:53:01Z","timestamp":1790801581871,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Paradoxical psoriasis occurs in pediatric patients following treatment with biologic agents. These presentations are not well described, and optimal treatment strategies have not been established.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe the reported rates, demographic characteristics, clinical presentation, and treatment options for TNF\u2010\u03b1 inhibitor\u2013induced psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Systematic review of published cases and cohort studies of paradoxical psoriasis induced by biologic agents, with specific reference to TNF\u2010\u03b1 inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 4564 pediatric patients treated with TNF\u2010\u03b1 inhibitors, of whom 210 (4.6%) developed paradoxical psoriasis. Infliximab was the drug most likely to induce psoriasis (8.3%), followed by adalimumab (3.3%). Individual\u2010level data were acquired from 129 individuals with a mean age of 13.6\u00a0years (SD: 4.0); 45.0% were male. The scalp was the most commonly affected area (47.5%), followed by the ears (30.8%). Most (63.3%) patients were continued on TNF\u2010\u03b1 inhibitor therapy. Among those who switched TNF\u2010\u03b1 inhibitors, only 32.0% had complete clearance of their skin lesions. Among patients who were switched to a non\u2010TNF\u2010\u03b1 inhibitor, 81% had complete clearance of their paradoxical psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Limitations<\/jats:title><jats:p>Data were acquired from retrospective studies including case reports and case series.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>TNF\u2010\u03b1 inhibitor\u2013induced psoriasis is a common adverse effect; however, most patients can continue their original therapy and be managed with skin\u2010directed topical or systemic medications. If a patient requires medication discontinuation, switching to a new TNF\u2010\u03b1 inhibitor is unlikely to lead to resolution of their skin lesions.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pde.14712","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T03:55:46Z","timestamp":1629172546000},"page":"1086-1093","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Paradoxical psoriasis in pediatric patients: A systematic review"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-4983","authenticated-orcid":false,"given":"Benoit M.","family":"Cyrenne","sequence":"first","affiliation":[{"name":"Division of Dermatology Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa S.","family":"Parpia","sequence":"additional","affiliation":[{"name":"Department of Epidemiology of Microbial Disease Yale School of Public Health New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9288-1121","authenticated-orcid":false,"given":"Cathryn","family":"Sibbald","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Medicine University of Toronto Toronto ON Canada"},{"name":"The Hospital for Sick Children University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24100"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001455"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525\u20101470.2011.01521.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.012"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.015"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/2475530318810851"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.010"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13081"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102133.2009.09593.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.12.1537"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572\u20100241.1990.tb06788.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20103083.2008.03031.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049\u20100172(88)90011\u2010X"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272\u2010015\u20100137\u20101"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000429"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.029"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2000.107840"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012448.pub2"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.02.1146"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20954"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12932"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13791"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12072"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14072"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.023"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010017\u20100296\u20107"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31828390ba"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102012\u2010302853"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217873"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2015.53"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.017"},{"issue":"10","key":"e_1_2_7_33_1","first-page":"1133","article-title":"Psoriasis targeted therapy: characterization of interleukin 17A expression in subtypes of psoriasis","volume":"14","author":"Lee E","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.082842"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15\u20100729"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1159\/000431171"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.14712","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pde.14712","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.14712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:08:37Z","timestamp":1696536517000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.14712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/pde.14712"],"URL":"https:\/\/doi.org\/10.1111\/pde.14712","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"2020-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}